Balloon Valvuloplasty for Congenital Aortic Stenosis: Experience at a Tertiary Center in a Developing Country
| Autor: | Ziad Bulbul, Haytham Bou Houssein, Issam El-Rassi, Anas Tabbakh, Nadine Kibbi, Mariam Arabi, Fatme Charafeddine, Fadi Bitar, Nour K. Younis, Mohammad S Abutaqa |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
Aortic valve
Balloon Valvuloplasty Male medicine.medical_specialty Percutaneous Heart disease Article Subject medicine.medical_treatment Coarctation of the aorta 030204 cardiovascular system & hematology 03 medical and health sciences 0302 clinical medicine medicine Diseases of the circulatory (Cardiovascular) system Humans Radiology Nuclear Medicine and imaging 030212 general & internal medicine Lebanon Retrospective Studies business.industry Infant Newborn Infant Perioperative Aortic Valve Stenosis medicine.disease Surgery Aortic valvuloplasty medicine.anatomical_structure Treatment Outcome RC666-701 Aortic valve stenosis Aortic Valve Female Cardiology and Cardiovascular Medicine Complication business Research Article |
| Zdroj: | Journal of Interventional Cardiology Journal of Interventional Cardiology, Vol 2021 (2021) |
| ISSN: | 1540-8183 0896-4327 |
| Popis: | Background. Aortic valve stenosis accounts for 3–6% of congenital heart disease. Balloon aortic valvuloplasty (BAV) is the preferred therapeutic intervention in many centers. However, most of the reported data are from developed countries. Materials and Methods. We performed a retrospective single-center study involving consecutive eligible neonates and infants with congenital aortic stenosis admitted for percutaneous BAV between January 2005 and January 2016 to our tertiary center. We evaluated the short- and mid-term outcomes associated with the use of BAV as a treatment for congenital aortic stenosis (CAS) at a tertiary center in a developing country. Similarly, we compared these outcomes to those reported in developed countries. Results. During the study period, a total of thirty patients, newborns (n = 15) and infants/children (n = 15), underwent BAV. Left ventricular systolic dysfunction was present in 56% of the patients. Isolated AS was present in 19 patients (63%). Associated anomalies were present in 11 patients (37%): seven (21%) had coarctation of the aorta, two (6%) had restrictive ventricular septal defects, one had mild Ebstein anomaly, one had Shone’s syndrome, and one had cleft mitral valve. BAV was not associated with perioperative or immediate postoperative mortality. Immediately following the valvuloplasty, a more than mild aortic regurgitation was noted only in two patients (7%). A none-to-mild aortic regurgitation was noted in the remaining 93%. One patient died three months after the procedure. At a mean follow-up of 7 years, twenty patients (69%) had more than mild aortic regurgitation, and four patients (13%) required surgical intervention. Kaplan–Meier freedom from aortic valve reintervention was 97% at 1 year and 87% at 10 years of follow-up. Conclusion. Based on outcomes encountered at a tertiary center in a developing country, BAV is an effective and safe modality associated with low complication rates comparable to those reported in developed countries. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text